AstraZeneca’s Imfinzi Demonstrates Survival Benefit in Limited-Stage Small Cell Lung Cancer Study

1. AstraZeneca's Imfinzi (durvalumab) has shown statistically significant and clinically meaningful improvements in both overall survival and progression-free survival for patients with limited-stage small cell lung cancer (LS-SCLC) in the global Phase III ADRIATIC study.
2. Imfinzi is the first immunotherapy to demonstrate survival benefits in the LS-SCLC setting in a Phase III study.
3. Imfinzi is already approved for the treatment of extensive-stage SCLC (ES-SCLC) in various countries, including the United States, European Union, Japan, and China, based on data from the Phase III CASPIAN study.
4. Imfinzi is a human monoclonal antibody that blocks a tumor's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response.
5. Small-cell lung cancer is a highly aggressive form of cancer with a low five-year survival rate (15% to 30%).
6. Imfinzi generated sales of $4.2 billion in 2023 and is a key revenue driver for AstraZeneca's oncology portfolio.
7. AstraZeneca is focused on strengthening its oncology business through label expansions of existing cancer drugs and advancing its oncology pipeline candidates.
8. The ADRIATIC Phase III study involved patients with LS-SCLC whose disease had not progressed after concurrent chemoradiotherapy (cCRT).
9. Imfinzi has been approved for use in various cancer indications, including non-small cell lung cancer and bladder cancer.
10. AstraZeneca is a founding member of the Lung Ambition Alliance, working to accelerate innovation and deliver meaningful improvements for people with lung cancer.